Gregory M. Glenn

President, Research & Development at Novavax, Inc.

Gregory M. Glenn

Gregory M. Glenn

President, Research & Development at Novavax, Inc.

Overview
Career Highlights

Intercell USA, Inc.

RelSci Relationships

196

Birthday

1954

Age

67

Number of Awards

1

Contact Data
Trying to get in touch with Gregory M. Glenn? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Gregory M. Glenn likely has professional access to. A relationship does not necessarily indicate a personal connection.

General Counsel at Intercell USA, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Novavax, Inc.

Relationship likelihood: Strong

Co-Founder at Hookipa Pharma, Inc.

Relationship likelihood: Strong

Vice President, Medical & Regulatory Affairs at Intercell USA, Inc.

Relationship likelihood: Strong

Executive Vice President, Chief Legal Officer & Corporate Secretary at Novavax, Inc.

Relationship likelihood: Strong

Executive Vice President & Chief Human Resources Officer at Novavax, Inc.

Relationship likelihood: Strong

Chief Accounting Officer, Chief Financial Officer & Director at Hookipa Pharma, Inc.

Relationship likelihood: Strong

Vice President, Operations at Intercell USA, Inc.

Relationship likelihood: Strong

Co-President & Chief Executive Officer at Valneva SE

Relationship likelihood: Strong

Former Executive Director, Global Program Management at Novavax, Inc.

Relationship likelihood: Strong

Paths to Gregory M. Glenn
Potential Connections via
Relationship Science
You
Gregory M. Glenn
President, Research & Development at Novavax, Inc.
Education
Doctor of Medicine Degree

To develop Holy Spirit-empowered leaders through whole person education to impact the world.

Bachelor of Arts Degree in Biology & Chemistry

Whitman College is renowned for combining academic excellence, an unpretentious Northwest culture, and an engaging community. We are honored to attract students who represent the Whitman mosaic – down-to-earth, high achievers with diverse interests. We are proud of our campus and the diversity and accomplishments of our students, staff, and faculty. A Whitman education liberates minds, inspires spirit and unleashes imagination. It fosters relationships that last a lifetime. We value community – on campus and off. Whitman holds dear the traditions and value of a liberal arts education, yet the college continually evolves itself to ensure that graduates are prepared for futures that offer limitless possibilities.

Career History
President, Research & Development
2010 - Current

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Founder
1997 - 2008

Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD.

Chief Scientific Officer
2008 - Prior

Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria.

Investments
Details Hidden

Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD.

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
American Board of Pediatrics - Board Certified Pediatrician
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Gregory M. Glenn. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Gregory M. Glenn's profile does not indicate a business or promotional relationship of any kind between RelSci and Gregory M. Glenn.